MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

87.95 0.38

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

87.14

Máximo

90.3

Métricas clave
By Trading Economics
Ingresos	5.4M -48M
Ventas	6M 57M
Margen de beneficios	-82.974
Empleados	414
EBITDA	5.1M -43M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+56.18% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-502M 5.9B
Apertura anterior	87.57
Cierre anterior	87.95

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

75 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 abr 2026, 23:26 UTC

Acciones populares

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 abr 2026, 20:41 UTC

Principales Movimientos del Mercado

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 abr 2026, 23:49 UTC

Charlas de Mercado

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 abr 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline After Hitting Record High -- Market Talk

16 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 abr 2026, 22:51 UTC

Charlas de Mercado

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 abr 2026, 22:08 UTC

Ganancias

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Health Care Roundup: Market Talk

16 abr 2026, 20:49 UTC

Ganancias

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 abr 2026, 20:43 UTC

Ganancias

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 abr 2026, 20:40 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

16 abr 2026, 20:40 UTC

Charlas de Mercado

Ganancias

Netflix Says Engagement Quality Hits New High -- Market Talk

16 abr 2026, 20:30 UTC

Acciones populares

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 abr 2026, 20:25 UTC

Ganancias

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 abr 2026, 20:23 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 abr 2026, 20:19 UTC

Ganancias

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 abr 2026, 20:17 UTC

Ganancias

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 abr 2026, 20:17 UTC

Ganancias

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

56.18% repunte

Estimación a 12 Meses

Media 137.14 USD 56.18%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

75 / 348 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.